Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zenuzolac - GeneOne Life Science

Next Previous
Drug Profile

Zenuzolac - GeneOne Life Science

Alternative Names: GIT-027; GIT-27; GLS-1027; VGX-1027

Latest Information Update: 18 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OncoNOX
  • Developer GeneOne Life Science; Inovio Pharmaceuticals
  • Class Acetic acids; Anti-inflammatories; Isoxazoles; Small molecules
  • Mechanism of Action Cytokine inhibitors; Immunosuppressants; NF-kappa B inhibitors; NF-kappa B kinase inhibitors; P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II COVID-19 pneumonia
  • Phase I Diabetic nephropathies; Inflammation
  • Preclinical Ulcerative colitis; Uveitis
  • Discontinued Rheumatoid arthritis; Type 1 diabetes mellitus

Most Recent Events

  • 18 Sep 2025 Discontinued - Phase-I for Type 1 diabetes mellitus (In volunteers) in USA (PO)
  • 17 Sep 2025 Phase I development for Inflammation and Diabetic-nephropathies (Prevention) is ongoing (GeneOne Life Science pipeline, September 2025)
  • 17 Sep 2025 Discontinued - Phase-I for Rheumatoid arthritis (In volunteers) in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top